Ascletis selects a best-in-class once-monthly subcutaneously administered amylin receptor agonist, asc36, for clinical development

-in head-to-head non-human primate (nhp) studies, average observed half-life of asc36 was approximately 15 days, 3 -fold longer than petrelintide, which supports once-monthly subcutaneous (sq) dosing in humans. -asc36 demonstrated approximately 91 % greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese ( dio ) rat study.
ASC Ratings Summary
ASC Quant Ranking